NEW YORK (360Dx) – Saladax Biomedical said today that it has inked a non-exclusive agreement to license two Alzheimer's diagnostic tests to Siemens Healthineers.

The tests identify the amyloid beta 1-42 and tau biomarkers, two indicators of the early stages of Alzheimer's disease, in cerebrospinal fluid.

Saladax said that under the agreement, it will provide its "proprietary" raw materials, protocols, and intellectual property, and Siemens will commercialize both assays.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.